explore -WSS

explore

author：hotspot 2025-10-04 04:00:54 - browse：348

Nick Leschly - Bluebird Bio — Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： FDA's naming rule on biosimilars has undermined competition

knowledge

explore

knowledge

WSS

Covid vaccines: Private market messier than government rollout

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Menendez indictment could see pharma lose a key ally

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Abortion pill Supreme Court ruling could impact entire drug industry

Address the ethical violations that led to 'Three Identical Strangers'

hotspot

explore

focus

In Memoriam: Notable people who died in 2023

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Guidelines to prevent youth baseball injuries need more muscle

Steward Health Care has deal to sell doctor network to UnitedHealth

How one medical school became remarkably diverse

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Medicare proposal to cover medical devices draws a mixed reaction

Oprah kicked off a national conversation on obesity. Let's have it

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

FDA seeks to regulate lab

leisure time

FDA advisers vote against ALS treatment from BrainStorm

Medicare drug price negotiation program allowed for now

Mindstrong's demise and the future of mental health care

Supreme Court mifepristone arguments center on docs' right to sue

FDA seeks to regulate lab

Patient advocates debate FDA's accelerated approval process

knowledge

explore

knowledge

focus